Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis

References

• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl E, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen. Rivaroxaban (Xarelto) bij behandeling van pulmonale embolie. CvZ; 2014 [cited 2017 Sept]. The Hague, the Netherlands. Available from: https://www.zorginstituutnederland.nl/publicaties/rapport/2014/02/18/rivaroxaban-xarelto-bij-behandeling-van-pulmonale-embolie.
   Google Scholar
• Federation Dutch Thombotic Services (FNT). Samenvatting medische jaarverslagen. FNT; 2015 [cited 2016 Nov]. Leiden, the Netherlands. Available from: https://s3.eu-central-1.amazonaws.com/storage.topsite.nl/fnt.nl/uploads/docs/jaarverslagen/Medisch_Jaarverslag_2015.pdf.
   Google Scholar
• Mainardi L, Sörnmo L, Cerutti S. Understanding atrial fibrillation: the signal processing contribution, part II. Synth Lect Biomed Eng. 2008;3(1):1–139.
   Google Scholar
• Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007;28(22):2803–2817.
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107–114.
   PubMed Web of Science ®Google Scholar
• Ozaki A, Bartholomew J, Cleveland Clinic Foundation. Venous thromboembolism. CCF; 2012 [cited 2016 Nov]. Available from: http:/www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/venous-thromboembolism/.
   Google Scholar
• NHG werkgroep atriumfibrilleren. NHG standaard atriumfibrilleren. Huisarts Wet. 2013;56(8):392–401.
   Google Scholar
• Oudega R, Van Weert H, Stoffers H, et al. NHG-Standaard Diepe veneuze trombose en longembolie. Huisarts Wet. 2008;51(1):24–37.
   Google Scholar
• Van den Donk M, de Jong J, Geersing G, et al. Cumarinederivaten en DOAC’s voortaan gelijkwaardig. Huisarts Wet. 2016;59(9):406–409.
   Google Scholar
• Letter from the Dutch Ministry of Health to parliament: Herbeoordeling uitbreiding nadere voorwaarden rivaroxaban (Xarelto®) bij VTE. 2015 [cited 2017 Sept]. Dutch Ministry of Health Location: The Hague, the Netherlands. Available from: https://www.zorginstituutnederland.nl/publicaties/rapport/2015/07/06/rivaroxaban-xarelto-bij-diepveneuze-trombose-pulmonale-embolie-en-preventie-van-recidief-dvt-en-pe.
   Google Scholar
• Letter from the Dutch Ministry of Health to parliament: Kamerstuk Tweede Kamer der Staten-Generaal 29477 Geneesmiddelenbeleid nr. 207. 2012 [cited 2017 May]. Dutch Ministry of Health Location: The Hague, the Netherlands. Available from: https://zoek.officielebekendmakingen.nl/kst-29477-207.pdf.
   Google Scholar
• The National Thrombotic Service. Informatie over NOACs. NTS [cited 2017 May]. Ministry of Health: The Hague, the Netherlands. Available from: http://www.denationaletrombosedienst.nl/informatie-over/noacs.
   Google Scholar
• Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–3069, 3069a–3069k.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• EINSTEIN Investigators, Bauersachs R, Berkowitz S, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
   PubMed Web of Science ®Google Scholar
• EINSTEIN–PE Investigators, Büller H, Prins M, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297.
   PubMed Web of Science ®Google Scholar
• Prins M, Lensing A, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21.
   PubMedGoogle Scholar
• Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145–1153.
   PubMed Web of Science ®Google Scholar
• Ageno W, Mantovani LG, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016;3(1):e12–21.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Morrison RB. Cardiology patient pages. Pulmonary embolism and deep vein thrombosis. Circulation. 2002;106(12):1436–1438.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev. 2002;16(3):155–165.
   PubMed Web of Science ®Google Scholar
• Camm A. Real-world versus randomized trial outcomes in similar populations of rivaroxaban treated patients with non-valvular atrial fibrillation in ROCKET-AF and XANTUS: Abstract 084 presented at the American College of Cardiology (ACC) 66th annual scientific session and expo, Washington DC, USA, 17–19 March 2017.
   Google Scholar
• Zorginstituut Nederland (ZiN). Recommendation to the Minister of Health: reassessment dabigatran. ZiN [cited 2017 May]. Diemen, the Netherlands. Available from: https://www.zorginstituutnederland.nl/binaries/zinl/documenten/rapport/2012/06/06/dabigatran-pradaxa-bij-preventie-van-cerebrovasculair-accident/Dabigatran+%28Pradaxa%29+bij+preventie+van+cerebrovasculair+accident.pdf.
   Google Scholar
• Dutch Healthcare Institute. Farmacotherapeutisch kompas, preparaattekst rivaroxaban. DHI [cited 2017 May]. Diemen, the Netherlands. Available from: https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/r/rivaroxaban#dosering.
   Google Scholar
• Federation Dutch Thombotic Services (FNT). Samenvatting medische jaarverslagen. FNT; 2014 [cited 2016 Nov]. Leiden, the Netherlands. Available from: https://s3.eu-central-1.amazonaws.com/storage.topsite.nl/fnt.nl/uploads/docs/jaarverslagen/FNT_Samenvatting_Medisch_JV_2014.pdf.
   Google Scholar
• Zorginstituut Nederland (ZiN). Dutch Drug reimbursement [cited 2016 Nov]. The Hague, the Netherlands. Available from: https://www.medicijnkosten.nl/.
   Google Scholar
• Nederlandse Zorgautoriteit (NZa). Table of Dutch healthcare product tariffs (2016). [cited 2017 Jan]. Utrecht, the Netherlands. Available from: https://www.nza.nl/regelgeving/tarieven-en-prestaties/20150710_Tarieventabel_DBC_zorgproducten_en_overige_producten_per_1_januari_2016.
   Google Scholar
• Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, et al. Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. In opdracht van Zorginstituut Nederland. Geactualiseerde versie 2015.
   Google Scholar
• Federation of Dutch Thrombosis Services (FNT). Adjustment of INR cut-off points. Leiden, the Netherlands. 2015; Available from: https://www.fnt.nl/nieuws/therapeutische-waarden-aangepast-5.
   Google Scholar
• Pisters R, van Vugt SPG, Brouwer MA, et al. Real-life use of rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J. 2017 Oct;25(10):551–558.
   Google Scholar
• Bamber L, Muston D, McLeod E, et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J. 2015;13:20-015–0051-3. eCollection 1–2, 2015.
   Web of Science ®Google Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31(10):909–918.
   PubMed Web of Science ®Google Scholar
• Mensch A, Stock S, Stollenwerk B, et al. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2015;33(3):271–283.
   PubMed Web of Science ®Google Scholar
• Baeten S, van Exel N, Dirks M, et al. Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc. 2010;8(21):7547–7548.
   Google Scholar
• Stevanovic J, de Jong LA, Kappelhoff BS, et al. Dabigatran for the treatment and secondary prevention of venous thromboembolism; a cost-effectiveness analysis for the Netherlands. PLoS One. 2016;11(10):e0163550.
   PubMed Web of Science ®Google Scholar
• van Leent MW, Stevanovic J, Jansman FG, et al. Cost-effectiveness of dabigatran compared to vitamin-K antagonists for the treatment of deep venous thrombosis in the Netherlands using real-world data. PLoS One. 2015;10(8):e0135054.
   PubMed Web of Science ®Google Scholar
• Stevanovic J, Pompen M, Le HH, et al. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS One. 2014;9(8):e103974.
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen (Zorginstituut Nederland, ZiN). Recommendation to the minister: assessment rivaroxaban. CvZ; 2012 [cited 2017 Jan]. The Hague, Netherlands. Available from: https://www.zorginstituutnederland.nl/binaries/zinl/documenten/rapport/2012/10/26/rivaroxaban-xarelto-bij-preventies-bij-diep-veneuze-trombose-dvt/Rivaroxaban+%28Xarelto%29+bij+preventies+bij+Diep+veneuze+trombose+%28DVT%29.pdf.
   Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014;30(5):829–837.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther. 2015;37(3):554–562.
   PubMed Web of Science ®Google Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4(1):49–56.
   PubMed Web of Science ®Google Scholar
• Ahmad Y, Lip GY. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart. 2012;98(19):1404–1406.
   PubMed Web of Science ®Google Scholar
• Robinson A, Thomson R, Parkin D, et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy. 2001;6(2):92–98.
   PubMedGoogle Scholar